PanCAN 2nd annual Therapeutic Accelerator Award Goes to ONCY PanCAN continues to accelerate new treatment options for patients with pancreatic cancer through the announcement of a $5 million grant to a biotechnology company at the leading edge of drug development.
The recipient of PanCAN’s second annual Therapeutic Accelerator Award, Oncolytics Biotech® Inc., was chosen through a rigorous review process for its promising work on an investigational treatment combination that uses an oncolytic virus called pelareorep to activate the body’s immune system to kill off pancreatic cancer cells. Clinical data has shown the treatment combination results in the recruitment and activation of cancer-fighting immune cells, including natural killer cells, dendritic cells, and T-cells, leading to a robust immune response focused specifically on cancer cells while sparing healthy cells.
https://pancan.org/news/pancans-5-million-therapeutic-accelerator-award-goes-to-oncolytics-biotech-inc/